Sugi Predict

Sugi Predict / Compounds / SCHEMBL1726948

SCHEMBL1726948

SCHEMBL1726948

CC(=O)OC[C@H]1O[C@@H](OC(=N)C(Cl)(Cl)Cl)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.59
▸ THRB P10828 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ NR3C1 P04150 1/20 0.51
▸ FYN P06241 1/20 0.51
▸ ADRA2A P08913 1/20 0.51
▸ ADORA3 P0DMS8 1/20 0.51
▸ ADRA2B P18089 1/20 0.51
▸ DRD4 P21917 1/20 0.51
▸ DRD3 P35462 1/20 0.51
▸ CA2 P00918 7/20 0.51
▸ TSHR P16473 1/20 0.48
▸ CA12 O43570 6/20 0.47
▸ CA1 P00915 5/20 0.47
▸ CA9 Q16790 4/20 0.47
▸ MAPT P10636 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ CA4 P22748 2/20 0.45
▸ CA5A P35218 2/20 0.45
▸ CA7 P43166 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15747016 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL17724779 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL20033571 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL17192718 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL1687338 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL18105805 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL15040789 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL414930 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL8515524 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN
SCHEMBL19304535 1.00 CYP2D6 (0.59) CYP2D6THRBHSD17B10NR3C1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3487318-B1 GLUCOSYRINGIC ACID ANALOGS AS SWEETNESS PROFILE MODIFIERS PEPSICO INC (US) 2026-04-01 — — EP disclosed
US-11325937-B2 Glycoside compound and preparation method therefor, composition, application, and intermediate SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) 2022-05-10 — — US disclosed
US-20210115082-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) 2021-04-22 — — US disclosed
US-10966447-B2 Glucosyringic acid analogs as sweetness profile modifiers PEPSICO, INC. (US) 2021-04-06 — — US disclosed
US-10966447-B2 Glucosyringic acid analogs as sweetness profile modifiers PEPSICO, INC. (US) 2021-04-06 — — US disclosed
EP-3214090-B1 THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FUJIFILM CORP (JP) 2020-08-19 — — EP disclosed
US-10385089-B2 Thionucleoside derivative or salt thereof, and pharmaceutical composition FUJIFILM CORPORATION (JP) 2019-08-20 — — US disclosed
US-20190085007-A1 4-methylcatechol Derivatives and Uses Thereof Thanares GmbH (DE) 2019-03-21 — — US disclosed
US-20180319834-A1 THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FUJIFILM CORPORATION (JP) 2018-11-08 — — US disclosed
US-10059734-B2 Thionucleoside derivative or salt thereof, and pharmaceutical composition FUJIFILM CORPORATION (JP) 2018-08-28 — — US disclosed
US-7053060-B2 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2006-05-30 — — US disclosed
EP-1609798-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2005-12-28 — — EP disclosed
US-20050113315-A1 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof KISSEI PHARMACEUTICAL CO., LTD. 2005-05-26 — — US disclosed
US-20050059614-A1 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof KISSEI PHARMACEUTICAL CO., LTD. 2005-03-17 — — US disclosed
US-20040138148-A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2004-07-15 — — US disclosed
US-20040063170-A1 Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 — — US disclosed
US-20040018998-A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same KISSEI PHARMACEUTICAL CO., LTD. (JP) 2004-01-29 — — US disclosed
EP-1367060-A1 GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2003-12-03 — — EP disclosed
EP-1344780-A1 GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2003-09-17 — — EP disclosed
US-4880917-A Process for hydrolyzing 2,6-dideoxy-2,6-iminoheptononitrile derivatives using trifluoroacetic acid and dinitrogen tetroxide MERRELL DOW PHARMACEUTICALS INC. (US) 1989-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138148-A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof SLC5A2, SLC5A1, SLC2A1 CYP2D6 207/4885THRB 1494/4885HSD17B10 186/4885
US-20190085007-A1 4-methylcatechol Derivatives and Uses Thereof ST3GAL3, GALE, DPP4 CYP2D6 111/4885THRB 4350/4885HSD17B10 468/4885
US-20180319834-A1 THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION SLC11A2, RNASE1, KRAS CYP2D6 2529/4885THRB 2448/4885HSD17B10 674/4885
US-10385089-B2 Thionucleoside derivative or salt thereof, and pharmaceutical composition SLC11A2, RNASE1, KRAS CYP2D6 2529/4885THRB 2448/4885HSD17B10 674/4885
US-10966447-B2 Glucosyringic acid analogs as sweetness profile modifiers GPR119, TAS2R42, TAS2R31 CYP2D6 3857/4885THRB 1167/4885HSD17B10 4059/4885
US-10059734-B2 Thionucleoside derivative or salt thereof, and pharmaceutical composition SLC11A2, RNASE1, TYMP CYP2D6 2481/4885THRB 2449/4885HSD17B10 687/4885
US-11325937-B2 Glycoside compound and preparation method therefor, composition, application, and intermediate VEGFA, FLT4, FLT1 CYP2D6 2650/4885THRB 3962/4885HSD17B10 2192/4885
US-20050113315-A1 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof SLC5A2, SLC5A1, SLC2A2 CYP2D6 338/4885THRB 1285/4885HSD17B10 164/4885
US-20040018998-A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same SLC5A2, SLC5A1, SLC2A1 CYP2D6 163/4885THRB 1384/4885HSD17B10 250/4885
US-20050059614-A1 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof SLC5A2, SLC5A1, SLC2A2 CYP2D6 319/4885THRB 1231/4885HSD17B10 139/4885
US-20210115082-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE VEGFA, FLT4, FLT1 CYP2D6 2650/4885THRB 3962/4885HSD17B10 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.